1.Sun Z#, Zhang H#, Zhang Y#, Liao L#, Zhou W#, Zhang F, Lian F, Huang J, Xu P, Zhang R, Lu W, Zhu M, Tao H, Yang F, Ding H, Chen S, Yue L, Zhou B, Zhang N, Tan M, Jiang H, Chen K, Liu B*, Liu C*, Dang Y*, Luo C*. Covalent Inhibitors Allosterically Block the Activation of Rho Family Proteins and Suppress Cancer Cell Invasion. Adv Sci (Weinh). 2020 May 13;7(14):2000098.
2.Fan S#, Yue L#, Wan W#, Zhang Y#, Zhang B#, Otomo C, Li Q, Lin T, Hu J, Xu P, Zhu M, Tao H, Chen Z, Li L, Ding H, Yao Z, Lu J, Wen Y, Zhang N, Tan M, Chen K, Xie Y, Otomo T, Zhou B*, Jiang H*, Dang Y*, Luo C*,. Inhibition of autophagy by a small molecule through covalent modification of LC3. Angew Chem Int Ed Engl. 2021 Sep 29.
3.Wang J#, Wang C#, Xu P#, Li X, Lu Y, Jin D, Yin X, Jiang H, Huang J, Xiong H, Ye F, Jin J, Chen Y, Xie Y, Chen Z, Ding H, Zhang H, Liu R, Jiang H, Chen K, Yao Z, Luo C, Huang Y*, Zhang Y*, Zhang J*. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics. 2021 Mar 12;11(11):5387-5403.
4.Zhou XR#, Li X#, Liao LP#, Han J, Huang J, Li JC, Tao HR, Fan SJ, Chen ZF, Li Q, Chen SJ, Ding H, Yang YX, Zhou B, Jiang HL, Chen KX, Zhang YY*, Huang CX*, Luo C*. P300/CBP inhibition sensitizes mantle cell lymphoma to PI3K inhibitor idelalisib. Acta Pharmacol Sin. 2021 Apr 13.
5.Huang HM#, Fan SJ#, Zhou XR#, Liu YJ, Li X, Liao LP, Huang J, Shi CC, Yu L, Fu R, Fan JG, Zhang YY*, Luo C*, Li GM*. Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacol Sin. 2021 Aug 2.
6.Liu Y#, Li J#, Liao L#, Huang H, Fan S, Fu R, Huang J, Shi C, Yu L, Chen KX, Zhang YY*, Luo C*, Li GM*. Cyclin-dependent kinase inhibitor roscovitine attenuates liver inflammation and fibrosis by influencing initiating steps of liver injury. Clin Sci (Lond). 2021 Apr 16;135(7):925-941.
7.Peng J#, Li J#, Huang J#, Xu P, Huang H, Liu Y, Yu L, Yang Y, Zhou B, Jiang H, Chen K, Dang Y, Zhang Y*, Luo C*, Li G*. p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization. Theranostics. 2019 Oct 22;9(26):8344-8361.
8.Chen W#, Zhang H#, Chen Z#, Jiang H, Liao L, Fan S, Xing J, Xie Y, Chen S, Ding H, Chen K, Jiang H, Luo C, Zheng M, Yao Z*, Huang Y*, Zhang Y*. Development and evaluation of a novel series of Nitroxoline-derived BET inhibitors with antitumor activity in renal cell carcinoma. Oncogenesis. 2018 Nov 2;7(11):83.
9.Wang C#, Jiang H#, Jin J#, Xie Y, Chen Z, Zhang H, Lian F, Liu YC, Zhang C, Ding H, Chen S, Zhang N, Zhang Y*, Jiang H, Chen K, Ye F*, Yao Z*, Luo C*. Development of Potent Type I Protein Arginine Methyltransferase (PRMT) Inhibitors of Leukemia Cell Proliferation. J Med Chem. 2017 Nov 9;60(21):8888-8905.
10.Zhang Y#, Wang Y#, Wei Y#, Wu J, Zhang P, Shen S, Saiyin H, Wumaier R, Yang X, Wang C*, Yu L*. Molecular chaperone CCT3 supports proper mitotic progression and cell proliferation in hepatocellular carcinoma cells. Cancer Lett. 2016 Mar 1;372(1):101-9.